Merck Announces FDA Acceptance of Supplemental New Drug Application for ISENTRESS® (raltegravir) in Adult Patients ... (Business Wire via Yahoo! Finance) PDF Print

WHITEHOUSE STATION, N.J.----Merck & Co., Inc. today announced that the U.S. Food and Drug Administration has accepted the supplemental New Drug Application filing for ISENTRESS® Tablets for standard review.

read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.